Details of the Drug

General Information of Drug (ID: DMNMXR8)

Drug Name
Procainamide
Synonyms
Biocoryl; Novocainamid; Novocainamide; Novocamid; Procainamida; Procainamidum; Procamide; Procan; Procanbid; Procapan; Pronestyl; Novocaine amide; Procaine amide; P-Aminobenzoic diethylaminoethylamide; Procainamida [INN-Spanish]; Procainamide (INN); Procainamide [INN:BAN]; Procainamidum [INN-Latin]; Procan (TN); Procanbid (TN); Procapan (free base); Pronestyl (TN); Pronestyl-Sr; P-Amino-N-(2-diethylaminoethyl)benzamide; Benzamide, 4-amino-N-(2-(diethylamino)ethyl)-(9CI); 2-Diethylaminoethylamid kyseliny p-aminobenzoove; 2-Diethylaminoethylamid kyseliny p-aminobenzoove [Czech]; 4-Amino-N-(2-(Diethylamino)Ethyl)Benzamide Sulfate; 4-Amino-N-(2-(diethylamino)ethyl)benzamide; 4-Amino-N-[2-(diethylamino)ethyl]benzamide; 4-amino-N-(2-diethylaminoethyl)-benzamide; 4-amino-N-(2-diethylaminoethyl)benzamide
Indication
Disease Entry ICD 11 Status REF
Ventricular arrhythmias BC71 Approved [1], [2]
Therapeutic Class
Antiarrhythmic Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 235.33
Topological Polar Surface Area (xlogp) 0.9
Rotatable Bond Count (rotbonds) 6
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 3
ADMET Property
Absorption
The absorption of drug is 75 to 95% [3]
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [4]
Bioavailability
83% of drug becomes completely available to its intended biological destination(s) [5]
Clearance
The drug present in the plasma can be removed from the body at the rate of 10 mL/min/kg [6]
Elimination
67% of drug is excreted from urine in the unchanged form [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 2.5 - 4.5 hours [6]
Metabolism
The drug is metabolized via the hepatic [3]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 212.46596 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.84% [6]
Vd
The volume of distribution (Vd) of drug is 2 L/kg [8]
Water Solubility
The ability of drug to dissolve in water is measured as 4 mg/mL [4]
Chemical Identifiers
Formula
C13H21N3O
IUPAC Name
4-amino-N-[2-(diethylamino)ethyl]benzamide
Canonical SMILES
CCN(CC)CCNC(=O)C1=CC=C(C=C1)N
InChI
InChI=1S/C13H21N3O/c1-3-16(4-2)10-9-15-13(17)11-5-7-12(14)8-6-11/h5-8H,3-4,9-10,14H2,1-2H3,(H,15,17)
InChIKey
REQCZEXYDRLIBE-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
4913
ChEBI ID
CHEBI:8428
CAS Number
51-06-9
DrugBank ID
DB01035
TTD ID
D0U5SI
VARIDT ID
DR00292
INTEDE ID
DR1343

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
E3 ubiquitin-protein ligase COP1 (RFWD2) TT05DLS COP1_HUMAN Modulator [9]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [10]
Multidrug and toxin extrusion protein 2 (SLC47A2) DT3TX4H S47A2_HUMAN Substrate [11]
Multidrug and toxin extrusion protein 1 (SLC47A1) DTZGT0P S47A1_HUMAN Substrate [11]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [12]
N-acetyltransferase 1 (NAT1) DE7OAB3 ARY1_HUMAN Substrate [13]
RNA cytidine acetyltransferase (hALP) DEZV4AP NAT10_HUMAN Substrate [14]
N-acetyltransferase 2 (NAT2) DER7TA0 ARY2_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Procainamide
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Procainamide and Propafenone. Ventricular tachyarrhythmia [BC71] [58]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Procainamide and Flecainide. Ventricular tachyarrhythmia [BC71] [59]
Coadministration of a Drug Treating the Disease Different from Procainamide (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Procainamide and Ivosidenib. Acute myeloid leukaemia [2A60] [59]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Procainamide and Midostaurin. Acute myeloid leukaemia [2A60] [59]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Procainamide and Idarubicin. Acute myeloid leukaemia [2A60] [59]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Procainamide and Arn-509. Acute myeloid leukaemia [2A60] [59]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Procainamide and Gilteritinib. Acute myeloid leukaemia [2A60] [59]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Procainamide and Oliceridine. Acute pain [MG31] [59]
Emapalumab DMZG5WL Moderate Altered metabolism of Procainamide due to Emapalumab alters the formation of CYP450 enzymes. Adaptive immunity immunodeficiency [4A01] [60]
Siltuximab DMGEATB Moderate Altered metabolism of Procainamide due to Siltuximab alters the formation of CYP450 enzymes. Anemia [3A00-3A9Z] [60]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Procainamide and Ivabradine. Angina pectoris [BA40] [60]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Procainamide and Bepridil. Angina pectoris [BA40] [61]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Procainamide and Dronedarone. Angina pectoris [BA40] [59]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Procainamide and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [59]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Procainamide and Cilostazol. Arterial occlusive disease [BD40] [59]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Procainamide and Posaconazole. Aspergillosis [1F20] [59]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Levalbuterol. Asthma [CA23] [62]
Pirbuterol DMI5678 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Pirbuterol. Asthma [CA23] [63]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Procainamide and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [59]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Procainamide and Desipramine. Attention deficit hyperactivity disorder [6A05] [59]
Ofloxacin DM0VQN3 Major Increased risk of prolong QT interval by the combination of Procainamide and Ofloxacin. Bacterial infection [1A00-1C4Z] [64]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Procainamide and Clarithromycin. Bacterial infection [1A00-1C4Z] [59]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Procainamide and Sparfloxacin. Bacterial infection [1A00-1C4Z] [65]
Gemifloxacin DMHT34O Major Increased risk of prolong QT interval by the combination of Procainamide and Gemifloxacin. Bacterial infection [1A00-1C4Z] [65]
Norfloxacin DMIZ6W2 Major Increased risk of prolong QT interval by the combination of Procainamide and Norfloxacin. Bacterial infection [1A00-1C4Z] [65]
Levofloxacin DMS60RB Major Increased risk of prolong QT interval by the combination of Procainamide and Levofloxacin. Bacterial infection [1A00-1C4Z] [65]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Procainamide and Retigabine. Behcet disease [4A62] [59]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Procainamide and Eribulin. Breast cancer [2C60-2C6Y] [59]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Procainamide and Lapatinib. Breast cancer [2C60-2C6Y] [59]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Procainamide and Bosutinib. Breast cancer [2C60-2C6Y] [59]
Acetylcholine DMDF79Z Moderate Antagonize the effect of Procainamide when combined with Acetylcholine. Cataract [9B10] [66]
Iodipamide DMXIQYS Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Iodipamide. Cholelithiasis [DC11] [67]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Procainamide and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [59]
Umeclidinium DM4E8O9 Moderate Additive anticholinergic effects by the combination of Procainamide and Umeclidinium. Chronic obstructive pulmonary disease [CA22] [68]
Olodaterol DM62B78 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Olodaterol. Chronic obstructive pulmonary disease [CA22] [63]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Vilanterol. Chronic obstructive pulmonary disease [CA22] [62]
Tiotropium DMFDC0Q Moderate Additive anticholinergic effects by the combination of Procainamide and Tiotropium. Chronic obstructive pulmonary disease [CA22] [68]
Revefenacin DMMP5SI Moderate Additive anticholinergic effects by the combination of Procainamide and Revefenacin. Chronic obstructive pulmonary disease [CA22] [68]
Indacaterol DMQJHR7 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Indacaterol. Chronic obstructive pulmonary disease [CA22] [63]
Arformoterol DMYM974 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Arformoterol. Chronic obstructive pulmonary disease [CA22] [63]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Procainamide and Isoproterenol. Conduction disorder [BC63] [63]
Atracurium DM42HXN Moderate Additive neuromuscular blocking effects by the combination of Procainamide and Atracurium. Corneal disease [9A76-9A78] [66]
Mivacurium DM473VD Moderate Additive neuromuscular blocking effects by the combination of Procainamide and Mivacurium. Corneal disease [9A76-9A78] [66]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Procainamide and Halothane. Corneal disease [9A76-9A78] [59]
Pancuronium DMB0VY8 Moderate Additive neuromuscular blocking effects by the combination of Procainamide and Pancuronium. Corneal disease [9A76-9A78] [66]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Procainamide and Sevoflurane. Corneal disease [9A76-9A78] [59]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Procainamide and Probucol. Coronary atherosclerosis [BA80] [59]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Procainamide and Pasireotide. Cushing syndrome [5A70] [59]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Procainamide and Osilodrostat. Cushing syndrome [5A70] [59]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Procainamide and Sertraline. Depression [6A70-6A7Z] [59]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Procainamide and Escitalopram. Depression [6A70-6A7Z] [59]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Procainamide and Clomipramine. Depression [6A70-6A7Z] [59]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Procainamide and Doxepin. Depression [6A70-6A7Z] [59]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Procainamide and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [59]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Procainamide and Deutetrabenazine. Dystonic disorder [8A02] [59]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Procainamide and Ingrezza. Dystonic disorder [8A02] [59]
Diphenhydramine DMKQTBA Moderate Increased risk of prolong QT interval by the combination of Procainamide and Diphenhydramine. Episodic vestibular syndrome [AB31] [69]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Procainamide and Solifenacin. Functional bladder disorder [GC50] [59]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Procainamide and Sunitinib. Gastrointestinal stromal tumour [2B5B] [59]
Pilocarpine DMV9ADG Moderate Antagonize the effect of Procainamide when combined with Pilocarpine. Glaucoma [9C61] [70]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Procainamide and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [59]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Procainamide and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [71]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Procainamide and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [59]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Procainamide and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [59]
Polyethylene glycol DM4I1JP Major Increased risk of ventricular arrhythmias by the combination of Procainamide and Polyethylene glycol. Irritable bowel syndrome [DD91] [72]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Phenolphthalein. Irritable bowel syndrome [DD91] [59]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Procainamide and Crizotinib. Lung cancer [2C25] [59]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Procainamide and Ceritinib. Lung cancer [2C25] [59]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Procainamide and Osimertinib. Lung cancer [2C25] [59]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Procainamide and Selpercatinib. Lung cancer [2C25] [59]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Procainamide and Lumefantrine. Malaria [1F40-1F45] [69]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Procainamide and Halofantrine. Malaria [1F40-1F45] [73]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Procainamide and Hydroxychloroquine. Malaria [1F40-1F45] [59]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Procainamide and Primaquine. Malaria [1F40-1F45] [59]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Procainamide and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [59]
Arsenic trioxide DM61TA4 Major Increased risk of ventricular arrhythmias by the combination of Procainamide and Arsenic trioxide. Mature B-cell lymphoma [2A85] [74]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Procainamide and Vemurafenib. Melanoma [2C30] [59]
LGX818 DMNQXV8 Major Increased risk of prolong QT interval by the combination of Procainamide and LGX818. Melanoma [2C30] [59]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Procainamide and Panobinostat. Multiple myeloma [2A83] [59]
Thalidomide DM70BU5 Moderate Increased risk of ventricular arrhythmias by the combination of Procainamide and Thalidomide. Multiple myeloma [2A83] [69]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Procainamide and Siponimod. Multiple sclerosis [8A40] [69]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Procainamide and Ocrelizumab. Multiple sclerosis [8A40] [75]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Procainamide and Ozanimod. Multiple sclerosis [8A40] [59]
Neostigmine DM6T2J3 Moderate Antagonize the effect of Procainamide when combined with Neostigmine. Myasthenia gravis [8C6Y] [76]
Romidepsin DMT5GNL Major Increased risk of prolong QT interval by the combination of Procainamide and Romidepsin. Mycosis fungoides [2B01] [59]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Procainamide and Nilotinib. Myeloproliferative neoplasm [2A20] [59]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Procainamide and Dasatinib. Myeloproliferative neoplasm [2A20] [59]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Procainamide and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [77]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Procainamide and Promethazine. Nausea/vomiting [MD90] [59]
Metoclopramide DMFA5MY Moderate Antagonize the effect of Procainamide when combined with Metoclopramide. Nausea/vomiting [MD90] [78]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Procainamide and Entrectinib. Non-small cell lung cancer [2C25] [59]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Procainamide and Levomethadyl Acetate. Opioid use disorder [6C43] [60]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Procainamide and Lofexidine. Opioid use disorder [6C43] [59]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Procainamide and Triclabendazole. Parasitic worm infestation [1F90] [59]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Procainamide and Pimavanserin. Parkinsonism [8A00] [59]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Procainamide and Macimorelin. Pituitary gland disorder [5A60-5A61] [79]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Procainamide and Lefamulin. Pneumonia [CA40] [80]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Procainamide and Degarelix. Prostate cancer [2C82] [59]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Procainamide and ABIRATERONE. Prostate cancer [2C82] [59]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Procainamide and Enzalutamide. Prostate cancer [2C82] [59]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Procainamide and Relugolix. Prostate cancer [2C82] [59]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Procainamide and Bicalutamide. Prostate cancer [2C82] [59]
Ustekinumab DMHTYK3 Moderate Altered metabolism of Procainamide due to Ustekinumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [60]
Ixekizumab DMXW92T Moderate Altered metabolism of Procainamide due to Ixekizumab alters the formation of CYP450 enzymes. Psoriasis [EA90] [60]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Procainamide and Levomepromazine. Psychotic disorder [6A20-6A25] [59]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Procainamide and Gatifloxacin. Respiratory infection [CA07-CA4Z] [65]
Tocilizumab DM7J6OR Moderate Altered metabolism of Procainamide due to Tocilizumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [60]
Canakinumab DM8HLO5 Moderate Altered metabolism of Procainamide due to Canakinumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [60]
Rilonacept DMGLUQS Moderate Altered metabolism of Procainamide due to Rilonacept alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [60]
Golimumab DMHZV7X Moderate Altered metabolism of Procainamide due to Golimumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [60]
Sarilumab DMOGNXY Moderate Altered metabolism of Procainamide due to Sarilumab alters the formation of CYP450 enzymes. Rheumatoid arthritis [FA20] [60]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Procainamide and Quetiapine. Schizophrenia [6A20] [59]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Procainamide and Aripiprazole. Schizophrenia [6A20] [69]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Procainamide and Iloperidone. Schizophrenia [6A20] [59]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Procainamide and Paliperidone. Schizophrenia [6A20] [59]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Procainamide and Amisulpride. Schizophrenia [6A20] [59]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Procainamide and Asenapine. Schizophrenia [6A20] [59]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Procainamide and Pimozide. Schizophrenia [6A20] [60]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Procainamide and LEE011. Solid tumour/cancer [2A00-2F9Z] [59]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Procainamide and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [81]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Procainamide and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [59]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Procainamide and Pitolisant. Somnolence [MG42] [59]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Procainamide and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [59]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Procainamide and Lenvatinib. Thyroid cancer [2D10] [59]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Procainamide and Cabozantinib. Thyroid cancer [2D10] [59]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Procainamide and Papaverine. Tonus and reflex abnormality [MB47] [82]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Procainamide and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [59]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Procainamide and Valganciclovir. Virus infection [1A24-1D9Z] [69]
⏷ Show the Full List of 126 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4811).
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 089257.
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 BDDCS applied to over 900 drugs
5 Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
6 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
9 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
10 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
11 Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
12 Involvement of CYP2D6 activity in the N-oxidation of procainamide in man. Pharmacogenetics. 1999 Dec;9(6):683-96.
13 Longitudinal distribution of arylamine N-acetyltransferases in the intestine of the hamster, mouse, and rat. Evidence for multiplicity of N-acetyltransferases in the intestine. Biochem Pharmacol. 1996 Nov 22;52(10):1613-20.
14 Effect of H2-receptor antagonists on rat liver cytosolic acetyl CoA:arylamine N-acetyltransferase activity. Drug Metab Dispos. 1992 Jan-Feb;20(1):74-8.
15 Substrate-dependent regulation of human arylamine N-acetyltransferase-1 in cultured cells. Mol Pharmacol. 2000 Mar;57(3):468-73.
16 Arylamine N-acetyltransferase in human red blood cells. Biochem Pharmacol. 1992 Sep 25;44(6):1099-104.
17 A population and family study of N-acetyltransferase using caffeine urinary metabolites. Clin Pharmacol Ther. 1993 Aug;54(2):134-41.
18 Crystallization and preliminary X-ray characterization of arylamine N-acetyltransferase C (BanatC) from Bacillus anthracis. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2007 Oct 1;63(Pt 10):862-4.
19 Identification of cytochrome P450 and arylamine N-acetyltransferase isoforms involved in sulfadiazine metabolism. Drug Metab Dispos. 2005 Jul;33(7):969-76.
20 Genetic analysis of bacterial acetyltransferases: identification of amino acids determining the specificities of the aminoglycoside 6'-N-acetyltransferase Ib and IIa proteins. J Bacteriol. 1992 May;174(10):3196-203.
21 NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis. Z Gastroenterol. 2008 Mar;46(3):259-65.
22 Xanthine oxidase inhibition by allopurinol affects the reliability of urinary caffeine metabolic ratios as markers for N-acetyltransferase 2 and CYP1A2 activities. Eur J Clin Pharmacol. 1999 Jan;54(11):869-76.
23 Aminoglycoside resistance resulting from tight drug binding to an altered aminoglycoside acetyltransferase. Antimicrob Agents Chemother. 2003 May;47(5):1577-83.
24 Effect of common NAT2 variant alleles in the acetylation of the major clonazepam metabolite, 7-aminoclonazepam. Drug Metab Lett. 2007 Jan;1(1):3-5.
25 Prizidilol, an antihypertensive with precapillary vasodilator and beta-adrenoceptor blocking actions, in primary hypertension. Clin Pharmacol Ther. 1981 May;29(5):588-93.
26 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
27 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
28 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
29 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
30 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
31 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
32 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
33 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
34 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
35 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
36 N-acetyltransferase 2 genotype-dependent N-acetylation of hydralazine in human hepatocytes. Drug Metab Dispos. 2017 Dec;45(12):1276-1281.
37 Genetic variation in aryl N-acetyltransferase results in significant differences in the pharmacokinetic and safety profiles of amifampridine (3,4-diaminopyridine) phosphate. Pharmacol Res Perspect. 2015 Feb;3(1):e00099.
38 Identification and functional characterization of arylamine N-acetyltransferases in eubacteria: evidence for highly selective acetylation of 5-aminosalicylic acid. J Bacteriol. 2001 Jun;183(11):3417-27.
39 Polymorphisms of Aspirin-Metabolizing Enzymes CYP2C9, NAT2 and UGT1A6 in Aspirin-Intolerant Urticaria. Allergy Asthma Immunol Res. 2011 Oct;3(4):273-6.
40 Importance of the evaluation of N-acetyltransferase enzyme activity prior to 5-aminosalicylic acid medication for ulcerative colitis. Inflamm Bowel Dis. 2016 Aug;22(8):1793-802.
41 Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
42 Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
43 Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
44 Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
45 FDA Drug Development and Drug Interactions
46 Expression of Organic Anion Transporter 1 or 3 in Human Kidney Proximal Tubule Cells Reduces Cisplatin Sensitivity. Drug Metab Dispos. 2018 May;46(5):592-599.
47 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
48 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
49 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
50 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
51 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
52 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
53 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
54 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
55 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
56 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
57 Barucainide, a novel class Ib antiarrhythmic agent with a slow kinetic property: electrophysiologic observations in isolated canine and rabbit cardiac muscle. Am Heart J. 1990 May;119(5):1050-60.
58 Buss J, Neuss H, Bilgin Y, Schlepper M "Malignant ventricular tachyarrhythmias in association with propafenone treatment." Eur Heart J 6 (1985): 424-8. [PMID: 4043097]
59 Canadian Pharmacists Association.
60 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
61 Hollingshead LM, Faulds D, Fitton A "Bepridil. A review of its pharmacological properties and therapeutic use in stable angina pectoris." Drugs 44 (1992): 835-57. [PMID: 1280569]
62 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
63 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
64 Martin DE, Shen J, Griener J, Raasch R, Patterson JH, Cascio W "Effects of ofloxacin on the pharmacokinetics and pharmacodynamics of procainamide." J Clin Pharmacol 36 (1996): 85-91. [PMID: 8932548]
65 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
66 Multum Information Services, Inc. Expert Review Panel.
67 Goernig M, Kirmeier T, Krack A, Hartog CS, Figulla HR, Leder U "Iohexol contrast medium induces QT prolongation in amiodarone patients." Br J Clin Pharmacol 58 (2004): 96-98. [PMID: 15206999]
68 Cole JM, Sheehan AH, Jordan JK "Concomitant use of ipratropium and tiotropium in chronic obstructive plmonary disease." Ann Pharmacother 46 (2012): 1717-21. [PMID: 23170031]
69 Cerner Multum, Inc. "Australian Product Information.".
70 Benjamin KW "Toxicity of ocular medications." Int Ophthalmol Clin 19 (1979): 199-255. [PMID: 376469]
71 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
72 Hill AG, Parry BR "Hypokalaemia following bowel cleansing with sodium phosphate." N Z Med J 109 (1996): 347. [PMID: 8862361]
73 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
74 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
75 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
76 Product Information. Mestinon (pyridostigmine). ICN Pharmaceuticals Inc, Cost Mesa, CA.
77 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
78 Product Information. Motilium (domperidone). Janssen-Ortho Inc, Toronto, ON.
79 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
80 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
81 Product Information. Vandetanib (vandetanib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
82 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]